A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome

法维皮拉维 医学 不利影响 内科学 临床试验 随机对照试验 病毒载量 多中心试验 死亡率 病毒 免疫学 多中心研究 疾病 2019年冠状病毒病(COVID-19) 传染病(医学专业)
作者
Koichiro Suemori,Masayuki Saijo,Atsushi Yamanaka,Daisuke Himeji,Masafumi Kawamura,Takashi Haku,Michihiro Hidaka,Chinatsu Kamikokuryo,Yasuyuki Kakihana,Taichi Azuma,Katsuto Takenaka,Toru Takahashi,Akitsugu Furumoto,Toshiyuki Ishimaru,Masayuki Ishida,Masahiko Kaneko,Norimitsu Kadowaki,Kenichi Ikeda,Shigetoshi Sakabe,Tomohiro Taniguchi
出处
期刊:PLOS Neglected Tropical Diseases [Public Library of Science]
卷期号:15 (2): e0009103-e0009103 被引量:58
标识
DOI:10.1371/journal.pntd.0009103
摘要

Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7–14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被小卢采纳,获得10
1秒前
369ninja发布了新的文献求助10
1秒前
AireenBeryl531举报笑笑的求助涉嫌违规
2秒前
Akim的应助被普鲁卡因采纳,获得10
3秒前
4秒前
daomaihu发布了新的文献求助100
4秒前
今后的应助被马大海采纳,获得10
4秒前
worldlet发布了新的文献求助10
4秒前
田様的应助被科研通管家采纳,获得10
4秒前
科目三的应助被科研通管家采纳,获得10
5秒前
无花果的应助被科研通管家采纳,获得10
5秒前
fan的应助被科研通管家采纳,获得10
5秒前
充电宝的应助被科研通管家采纳,获得10
5秒前
null的应助被科研通管家采纳,获得10
5秒前
脑洞疼的应助被科研通管家采纳,获得10
5秒前
小蘑菇的应助被科研通管家采纳,获得10
5秒前
null的应助被科研通管家采纳,获得10
5秒前
TH发布了新的文献求助30
5秒前
Akim的应助被科研通管家采纳,获得10
6秒前
赘婿的应助被科研通管家采纳,获得10
6秒前
inspire的应助被科研通管家采纳,获得10
6秒前
6秒前
大个的应助被科研通管家采纳,获得10
6秒前
6秒前
6秒前
余香的应助被科研通管家采纳,获得10
6秒前
香蕉觅云的应助被科研通管家采纳,获得30
6秒前
muxiangrong的应助被科研通管家采纳,获得10
7秒前
李爱国的应助被科研通管家采纳,获得10
7秒前
Orange的应助被科研通管家采纳,获得10
7秒前
TED的应助被科研通管家采纳,获得10
7秒前
江河湖海完成签到,获得积分10
7秒前
初景的应助被科研通管家采纳,获得20
7秒前
领导范儿的应助被科研通管家采纳,获得10
7秒前
null的应助被科研通管家采纳,获得10
7秒前
打打的应助被科研通管家采纳,获得10
8秒前
8秒前
NexusExplorer的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184336
求助须知:如何正确求助?哪些是违规求助? 9573358
关于积分的说明 21830993
捐赠科研通 7781367
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558401
邀请新用户注册赠送积分活动 2480846